 Rangaraj Selvarangan
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 25 | 2024 | 57 | 8.510 |
Why?
| | Enterovirus Infections | 19 | 2023 | 37 | 8.080 |
Why?
| | Respiratory Tract Infections | 21 | 2023 | 75 | 7.710 |
Why?
| | Parechovirus | 15 | 2023 | 19 | 7.200 |
Why?
| | Picornaviridae Infections | 14 | 2023 | 20 | 6.900 |
Why?
| | Molecular Diagnostic Techniques | 15 | 2022 | 36 | 6.290 |
Why?
| | Influenza A virus | 12 | 2023 | 20 | 5.690 |
Why?
| | Infant | 87 | 2024 | 1396 | 5.660 |
Why?
| | Humans | 156 | 2024 | 6599 | 5.590 |
Why?
| | Respiratory Syncytial Virus Infections | 12 | 2023 | 41 | 4.990 |
Why?
| | Child | 98 | 2024 | 3146 | 4.950 |
Why?
| | Influenza B virus | 13 | 2023 | 22 | 4.740 |
Why?
| | Respiratory Syncytial Virus, Human | 10 | 2023 | 23 | 4.510 |
Why?
| | Enterovirus | 8 | 2023 | 12 | 4.400 |
Why?
| | Enterovirus D, Human | 12 | 2023 | 25 | 4.290 |
Why?
| | Child, Preschool | 74 | 2023 | 1459 | 4.210 |
Why?
| | Gastroenteritis | 15 | 2023 | 24 | 4.010 |
Why?
| | Nucleic Acid Amplification Techniques | 6 | 2020 | 13 | 3.710 |
Why?
| | Anti-Bacterial Agents | 18 | 2023 | 238 | 3.150 |
Why?
| | Sensitivity and Specificity | 29 | 2023 | 145 | 3.130 |
Why?
| | Disease Outbreaks | 12 | 2023 | 30 | 3.050 |
Why?
| | Female | 71 | 2024 | 3436 | 2.890 |
Why?
| | Male | 67 | 2023 | 3197 | 2.860 |
Why?
| | United States | 47 | 2024 | 646 | 2.760 |
Why?
| | Rotavirus Infections | 12 | 2023 | 15 | 2.700 |
Why?
| | Adolescent | 50 | 2024 | 2087 | 2.640 |
Why?
| | Rotavirus Vaccines | 9 | 2023 | 13 | 2.620 |
Why?
| | Feces | 18 | 2023 | 37 | 2.510 |
Why?
| | Real-Time Polymerase Chain Reaction | 10 | 2023 | 38 | 2.450 |
Why?
| | Infant, Newborn | 34 | 2023 | 790 | 2.440 |
Why?
| | Central Nervous System Infections | 3 | 2021 | 5 | 2.420 |
Why?
| | Diagnostic Tests, Routine | 5 | 2019 | 17 | 2.360 |
Why?
| | Rotavirus | 9 | 2023 | 11 | 2.220 |
Why?
| | Nasopharynx | 12 | 2023 | 25 | 2.200 |
Why?
| | Prospective Studies | 27 | 2024 | 508 | 2.150 |
Why?
| | Antibodies, Viral | 11 | 2022 | 46 | 2.090 |
Why?
| | Norovirus | 5 | 2023 | 7 | 2.060 |
Why?
| | Bacteremia | 5 | 2021 | 25 | 1.930 |
Why?
| | Streptococcal Infections | 4 | 2020 | 19 | 1.910 |
Why?
| | Hospitalization | 20 | 2024 | 192 | 1.900 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 10 | 2020 | 64 | 1.820 |
Why?
| | Virus Diseases | 3 | 2022 | 11 | 1.770 |
Why?
| | Reagent Kits, Diagnostic | 9 | 2018 | 12 | 1.730 |
Why?
| | Virology | 5 | 2015 | 5 | 1.580 |
Why?
| | Urinary Tract Infections | 3 | 2021 | 17 | 1.550 |
Why?
| | Pneumonia, Mycoplasma | 6 | 2024 | 15 | 1.550 |
Why?
| | Young Adult | 19 | 2022 | 652 | 1.520 |
Why?
| | Influenza Vaccines | 7 | 2024 | 24 | 1.460 |
Why?
| | Adult | 24 | 2023 | 1233 | 1.450 |
Why?
| | Bacteriological Techniques | 5 | 2021 | 7 | 1.410 |
Why?
| | DNA, Viral | 4 | 2020 | 13 | 1.400 |
Why?
| | Point-of-Care Testing | 2 | 2020 | 7 | 1.400 |
Why?
| | Sepsis | 4 | 2018 | 22 | 1.360 |
Why?
| | Middle Aged | 16 | 2021 | 648 | 1.310 |
Why?
| | Mycoplasma pneumoniae | 5 | 2020 | 12 | 1.310 |
Why?
| | Emergency Service, Hospital | 7 | 2024 | 129 | 1.290 |
Why?
| | Retrospective Studies | 20 | 2023 | 1251 | 1.290 |
Why?
| | Aged | 13 | 2021 | 375 | 1.280 |
Why?
| | Clostridium Infections | 3 | 2020 | 7 | 1.260 |
Why?
| | Aged, 80 and over | 10 | 2021 | 150 | 1.230 |
Why?
| | Enterobacteriaceae Infections | 3 | 2023 | 10 | 1.230 |
Why?
| | Polymerase Chain Reaction | 6 | 2019 | 82 | 1.230 |
Why?
| | Staphylococcal Infections | 4 | 2016 | 21 | 1.200 |
Why?
| | Specimen Handling | 5 | 2021 | 18 | 1.200 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2023 | 11 | 1.190 |
Why?
| | Enterobacteriaceae | 3 | 2023 | 7 | 1.190 |
Why?
| | Staphylococcus aureus | 3 | 2016 | 18 | 1.180 |
Why?
| | Respiratory System | 3 | 2015 | 5 | 1.110 |
Why?
| | Cerebrospinal Fluid | 4 | 2020 | 8 | 1.100 |
Why?
| | Escherichia coli | 11 | 2023 | 27 | 1.080 |
Why?
| | Immunoassay | 4 | 2015 | 8 | 1.080 |
Why?
| | Genotype | 17 | 2022 | 395 | 1.070 |
Why?
| | Point-of-Care Systems | 3 | 2020 | 15 | 1.060 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2022 | 9 | 1.060 |
Why?
| | Influenza A Virus, H1N1 Subtype | 5 | 2024 | 12 | 1.060 |
Why?
| | Cephalosporins | 3 | 2023 | 15 | 1.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 50 | 1.050 |
Why?
| | Rhinovirus | 4 | 2023 | 11 | 1.030 |
Why?
| | Antibodies, Neutralizing | 5 | 2022 | 31 | 1.030 |
Why?
| | Microbial Sensitivity Tests | 13 | 2023 | 32 | 1.020 |
Why?
| | Missouri | 9 | 2023 | 78 | 1.020 |
Why?
| | Bodily Secretions | 2 | 2015 | 3 | 1.010 |
Why?
| | Seasons | 9 | 2023 | 27 | 1.000 |
Why?
| | Prevalence | 12 | 2023 | 145 | 0.990 |
Why?
| | Caliciviridae Infections | 3 | 2021 | 4 | 0.990 |
Why?
| | Streptococcus pyogenes | 3 | 2020 | 13 | 0.970 |
Why?
| | Vancomycin Resistance | 2 | 2014 | 4 | 0.920 |
Why?
| | Dysentery, Bacillary | 1 | 2023 | 2 | 0.920 |
Why?
| | Shigella | 1 | 2023 | 2 | 0.920 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 7 | 0.900 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 18 | 0.890 |
Why?
| | Inpatients | 3 | 2020 | 44 | 0.890 |
Why?
| | Pandemics | 8 | 2024 | 78 | 0.870 |
Why?
| | Coinfection | 1 | 2022 | 5 | 0.870 |
Why?
| | Automation, Laboratory | 2 | 2019 | 4 | 0.870 |
Why?
| | Population Surveillance | 6 | 2021 | 12 | 0.860 |
Why?
| | Pharyngitis | 2 | 2020 | 14 | 0.840 |
Why?
| | Viral Vaccines | 3 | 2022 | 10 | 0.830 |
Why?
| | Itraconazole | 2 | 2020 | 2 | 0.820 |
Why?
| | Triazoles | 2 | 2020 | 3 | 0.820 |
Why?
| | Time Factors | 8 | 2020 | 241 | 0.810 |
Why?
| | Asthma | 2 | 2023 | 143 | 0.810 |
Why?
| | Clinical Laboratory Techniques | 5 | 2021 | 9 | 0.810 |
Why?
| | Mass Screening | 2 | 2019 | 41 | 0.800 |
Why?
| | Bacterial Infections | 1 | 2021 | 27 | 0.790 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 19 | 0.790 |
Why?
| | Phlebotomy | 2 | 2011 | 2 | 0.780 |
Why?
| | Equipment Contamination | 2 | 2011 | 6 | 0.770 |
Why?
| | Phylogeny | 10 | 2022 | 21 | 0.770 |
Why?
| | Antiviral Agents | 4 | 2021 | 26 | 0.770 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2020 | 4 | 0.760 |
Why?
| | Vaccination | 12 | 2024 | 68 | 0.760 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 3 | 0.760 |
Why?
| | Antigens, Viral | 4 | 2022 | 7 | 0.750 |
Why?
| | Kansas | 4 | 2023 | 49 | 0.740 |
Why?
| | RNA Viruses | 1 | 2019 | 3 | 0.730 |
Why?
| | Urinalysis | 1 | 2019 | 5 | 0.720 |
Why?
| | Communicable Diseases, Emerging | 1 | 2019 | 3 | 0.700 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2019 | 6 | 0.700 |
Why?
| | Peritonitis | 2 | 2021 | 52 | 0.690 |
Why?
| | Drug Utilization | 1 | 2018 | 13 | 0.680 |
Why?
| | Molecular Typing | 1 | 2018 | 1 | 0.670 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2015 | 16 | 0.660 |
Why?
| | Paramyxoviridae Infections | 2 | 2022 | 12 | 0.640 |
Why?
| | Risk Factors | 8 | 2023 | 460 | 0.630 |
Why?
| | Peritoneal Dialysis | 2 | 2021 | 148 | 0.630 |
Why?
| | Bordetella Infections | 2 | 2014 | 2 | 0.630 |
Why?
| | Bordetella parapertussis | 2 | 2014 | 2 | 0.630 |
Why?
| | Severity of Illness Index | 6 | 2021 | 142 | 0.610 |
Why?
| | Escherichia coli Infections | 7 | 2017 | 17 | 0.610 |
Why?
| | Case-Control Studies | 10 | 2024 | 202 | 0.600 |
Why?
| | Carrier State | 2 | 2018 | 5 | 0.600 |
Why?
| | Adhesins, Escherichia coli | 9 | 2017 | 9 | 0.590 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 16 | 0.580 |
Why?
| | Fever | 4 | 2021 | 26 | 0.560 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 10 | 0.550 |
Why?
| | Sequence Analysis, DNA | 7 | 2019 | 106 | 0.540 |
Why?
| | Drug Resistance, Bacterial | 5 | 2020 | 14 | 0.540 |
Why?
| | Herpes Simplex | 2 | 2020 | 10 | 0.530 |
Why?
| | RNA, Viral | 3 | 2015 | 16 | 0.530 |
Why?
| | Pharynx | 3 | 2020 | 7 | 0.530 |
Why?
| | Mycoplasma | 1 | 2015 | 2 | 0.520 |
Why?
| | Mycoplasma Infections | 1 | 2015 | 2 | 0.520 |
Why?
| | Antigens, Bacterial | 3 | 2011 | 9 | 0.520 |
Why?
| | Bordetella pertussis | 1 | 2014 | 1 | 0.510 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 19 | 0.510 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 2 | 0.510 |
Why?
| | Animals | 12 | 2022 | 563 | 0.500 |
Why?
| | Viruses | 3 | 2022 | 5 | 0.500 |
Why?
| | Blood Specimen Collection | 2 | 2011 | 4 | 0.490 |
Why?
| | Macrolides | 5 | 2020 | 9 | 0.490 |
Why?
| | Vancomycin | 1 | 2014 | 17 | 0.480 |
Why?
| | Adenovirus Infections, Human | 2 | 2011 | 3 | 0.480 |
Why?
| | Virus Cultivation | 4 | 2015 | 4 | 0.480 |
Why?
| | Saliva | 3 | 2023 | 10 | 0.480 |
Why?
| | Genetic Variation | 3 | 2022 | 161 | 0.450 |
Why?
| | Vaccines | 2 | 2023 | 17 | 0.440 |
Why?
| | Metapneumovirus | 2 | 2022 | 12 | 0.440 |
Why?
| | Enterococcus | 1 | 2012 | 3 | 0.430 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2012 | 7 | 0.430 |
Why?
| | Paramyxoviridae | 1 | 2011 | 1 | 0.430 |
Why?
| | Streptococcus bovis | 1 | 2011 | 1 | 0.420 |
Why?
| | Meningitis, Bacterial | 1 | 2011 | 4 | 0.420 |
Why?
| | Influenza A Virus, H3N2 Subtype | 5 | 2023 | 11 | 0.410 |
Why?
| | Oligonucleotide Probes | 2 | 2009 | 4 | 0.410 |
Why?
| | Campylobacter Infections | 1 | 2011 | 2 | 0.410 |
Why?
| | False Positive Reactions | 1 | 2011 | 4 | 0.410 |
Why?
| | Adenoviruses, Human | 1 | 2011 | 1 | 0.400 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 10 | 0.400 |
Why?
| | Blood | 1 | 2011 | 10 | 0.400 |
Why?
| | Catheterization, Peripheral | 1 | 2011 | 5 | 0.400 |
Why?
| | Meningitis, Viral | 2 | 2022 | 2 | 0.390 |
Why?
| | Follow-Up Studies | 5 | 2021 | 315 | 0.390 |
Why?
| | Pediatric Nursing | 1 | 2010 | 5 | 0.380 |
Why?
| | Infection Control | 1 | 2010 | 7 | 0.370 |
Why?
| | Genotyping Techniques | 2 | 2020 | 21 | 0.370 |
Why?
| | Epidemiological Monitoring | 5 | 2021 | 6 | 0.350 |
Why?
| | Encephalitis, Viral | 1 | 2009 | 1 | 0.350 |
Why?
| | Simplexvirus | 1 | 2009 | 3 | 0.350 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 4 | 0.350 |
Why?
| | Streptococcus pneumoniae | 1 | 2009 | 5 | 0.340 |
Why?
| | Antifungal Agents | 2 | 2020 | 13 | 0.340 |
Why?
| | Mycobacterium | 2 | 2010 | 2 | 0.340 |
Why?
| | Schools | 3 | 2023 | 49 | 0.330 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 99 | 0.320 |
Why?
| | Pyelonephritis | 3 | 2004 | 4 | 0.310 |
Why?
| | Reproducibility of Results | 3 | 2012 | 197 | 0.300 |
Why?
| | beta-Lactamases | 3 | 2018 | 6 | 0.290 |
Why?
| | Acute Disease | 3 | 2022 | 71 | 0.280 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 23 | 0.270 |
Why?
| | Fucosyltransferases | 2 | 2015 | 2 | 0.270 |
Why?
| | Algorithms | 3 | 2020 | 103 | 0.270 |
Why?
| | Cluster Analysis | 4 | 2015 | 43 | 0.260 |
Why?
| | Immunity, Humoral | 2 | 2022 | 14 | 0.260 |
Why?
| | Immunization Programs | 2 | 2019 | 6 | 0.260 |
Why?
| | Cross Infection | 2 | 2017 | 12 | 0.260 |
Why?
| | Adhesins, Bacterial | 1 | 2004 | 1 | 0.250 |
Why?
| | Collagen Type IV | 1 | 2004 | 3 | 0.250 |
Why?
| | Escherichia coli Proteins | 1 | 2004 | 3 | 0.250 |
Why?
| | Cephalosporin Resistance | 3 | 2018 | 4 | 0.250 |
Why?
| | Candida | 1 | 2003 | 2 | 0.240 |
Why?
| | Fimbriae, Bacterial | 3 | 2001 | 3 | 0.240 |
Why?
| | Cytomegalovirus Infections | 1 | 2023 | 3 | 0.230 |
Why?
| | Azithromycin | 1 | 2023 | 5 | 0.230 |
Why?
| | Longitudinal Studies | 2 | 2020 | 123 | 0.230 |
Why?
| | Cohort Studies | 3 | 2021 | 264 | 0.230 |
Why?
| | Penicillanic Acid | 1 | 2023 | 2 | 0.230 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 7 | 0.230 |
Why?
| | Students | 1 | 2023 | 43 | 0.230 |
Why?
| | Oseltamivir | 2 | 2021 | 6 | 0.220 |
Why?
| | Coronavirus | 1 | 2022 | 2 | 0.220 |
Why?
| | Viral Fusion Proteins | 1 | 2022 | 4 | 0.220 |
Why?
| | Seroepidemiologic Studies | 2 | 2019 | 3 | 0.220 |
Why?
| | Craniocerebral Trauma | 1 | 2022 | 18 | 0.220 |
Why?
| | Midwestern United States | 2 | 2013 | 39 | 0.210 |
Why?
| | Hospitals, Pediatric | 3 | 2020 | 178 | 0.210 |
Why?
| | Child, Hospitalized | 3 | 2022 | 27 | 0.210 |
Why?
| | Critical Care | 3 | 2018 | 12 | 0.210 |
Why?
| | Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.210 |
Why?
| | Central Nervous System | 1 | 2021 | 7 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.210 |
Why?
| | Lung Diseases | 1 | 2021 | 23 | 0.200 |
Why?
| | Risk Assessment | 2 | 2020 | 130 | 0.200 |
Why?
| | Child Abuse | 1 | 2022 | 45 | 0.200 |
Why?
| | Cloud Computing | 1 | 2021 | 5 | 0.200 |
Why?
| | Disease Management | 2 | 2018 | 36 | 0.200 |
Why?
| | Lymphadenitis | 2 | 2013 | 3 | 0.200 |
Why?
| | Public Health Surveillance | 1 | 2020 | 5 | 0.200 |
Why?
| | Klebsiella Infections | 2 | 2017 | 3 | 0.190 |
Why?
| | ROC Curve | 1 | 2020 | 18 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 38 | 0.190 |
Why?
| | Coronavirus Infections | 1 | 2020 | 15 | 0.190 |
Why?
| | Quebec | 1 | 2020 | 4 | 0.190 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 16 | 0.190 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2020 | 2 | 0.190 |
Why?
| | Drug Resistance, Viral | 1 | 2020 | 3 | 0.190 |
Why?
| | DNA, Bacterial | 3 | 2011 | 5 | 0.190 |
Why?
| | Gastrointestinal Diseases | 1 | 2021 | 45 | 0.190 |
Why?
| | Canada | 1 | 2020 | 31 | 0.190 |
Why?
| | Mouth | 1 | 2020 | 3 | 0.190 |
Why?
| | Herpesvirus 1, Human | 1 | 2020 | 4 | 0.190 |
Why?
| | International Classification of Diseases | 1 | 2020 | 8 | 0.190 |
Why?
| | Family Health | 1 | 2020 | 14 | 0.190 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 24 | 0.190 |
Why?
| | Postoperative Care | 1 | 2020 | 28 | 0.190 |
Why?
| | Europe | 1 | 2020 | 33 | 0.180 |
Why?
| | Early Diagnosis | 1 | 2020 | 33 | 0.180 |
Why?
| | Immunoenzyme Techniques | 1 | 2019 | 9 | 0.180 |
Why?
| | Age Distribution | 1 | 2019 | 31 | 0.180 |
Why?
| | Prognosis | 1 | 2020 | 209 | 0.180 |
Why?
| | Gonorrhea | 2 | 2015 | 4 | 0.180 |
Why?
| | Molecular Epidemiology | 3 | 2017 | 6 | 0.180 |
Why?
| | History, 21st Century | 1 | 2019 | 5 | 0.170 |
Why?
| | Chronic Disease | 3 | 2012 | 103 | 0.170 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 3 | 0.170 |
Why?
| | Bacterial Typing Techniques | 2 | 2016 | 4 | 0.170 |
Why?
| | Immunization Schedule | 1 | 2019 | 7 | 0.170 |
Why?
| | Critical Pathways | 1 | 2018 | 9 | 0.170 |
Why?
| | Hematologic Diseases | 1 | 2018 | 4 | 0.170 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 8 | 0.170 |
Why?
| | False Negative Reactions | 1 | 2018 | 10 | 0.160 |
Why?
| | Vaccines, Attenuated | 4 | 2022 | 8 | 0.160 |
Why?
| | Intestines | 1 | 2018 | 26 | 0.160 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2017 | 2 | 0.160 |
Why?
| | Sapovirus | 1 | 2017 | 1 | 0.160 |
Why?
| | Cells, Cultured | 1 | 2017 | 73 | 0.160 |
Why?
| | Cell Line | 1 | 2017 | 80 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 92 | 0.150 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 2 | 0.150 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 28 | 0.150 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 96 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 215 | 0.150 |
Why?
| | Staphylococcal Skin Infections | 1 | 2016 | 3 | 0.150 |
Why?
| | Clindamycin | 1 | 2016 | 3 | 0.150 |
Why?
| | Length of Stay | 2 | 2018 | 227 | 0.140 |
Why?
| | Neoplasms | 1 | 2018 | 119 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 317 | 0.140 |
Why?
| | Recombination, Genetic | 1 | 2015 | 3 | 0.140 |
Why?
| | Virulence Factors | 1 | 2015 | 4 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2015 | 16 | 0.140 |
Why?
| | Hemoglobins | 1 | 2015 | 26 | 0.140 |
Why?
| | Adenoviridae | 2 | 2022 | 6 | 0.140 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 2 | 0.130 |
Why?
| | Trichomonas Vaginitis | 1 | 2015 | 2 | 0.130 |
Why?
| | Chlamydia Infections | 1 | 2015 | 3 | 0.130 |
Why?
| | Dogs | 1 | 2015 | 16 | 0.130 |
Why?
| | Equipment Failure | 1 | 2015 | 9 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2018 | 624 | 0.130 |
Why?
| | DNA, Ribosomal | 2 | 2011 | 3 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2011 | 7 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2015 | 13 | 0.130 |
Why?
| | Quality Improvement | 1 | 2015 | 60 | 0.120 |
Why?
| | Age Factors | 3 | 2021 | 203 | 0.120 |
Why?
| | Base Sequence | 2 | 2004 | 76 | 0.120 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 65 | 0.120 |
Why?
| | Mice | 3 | 2022 | 290 | 0.120 |
Why?
| | Incidence | 2 | 2011 | 125 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 10 | 0.120 |
Why?
| | Abscess | 1 | 2013 | 10 | 0.110 |
Why?
| | Viral Proteins | 1 | 2013 | 8 | 0.110 |
Why?
| | Diarrhea | 2 | 2011 | 18 | 0.110 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 21 | 0.110 |
Why?
| | Pneumococcal Infections | 2 | 2011 | 6 | 0.110 |
Why?
| | HeLa Cells | 5 | 2004 | 15 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2023 | 107 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 6 | 0.110 |
Why?
| | Immunity, Cellular | 2 | 2022 | 18 | 0.110 |
Why?
| | Epitopes | 2 | 2022 | 19 | 0.100 |
Why?
| | Enterotoxins | 1 | 2011 | 2 | 0.100 |
Why?
| | Exudates and Transudates | 1 | 2011 | 1 | 0.100 |
Why?
| | Middle Ear Ventilation | 1 | 2011 | 1 | 0.100 |
Why?
| | Campylobacter | 1 | 2011 | 2 | 0.100 |
Why?
| | Communicable Diseases | 1 | 2011 | 9 | 0.100 |
Why?
| | Serotyping | 1 | 2011 | 1 | 0.100 |
Why?
| | Restriction Mapping | 1 | 2011 | 5 | 0.100 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 2 | 0.100 |
Why?
| | Policy Making | 1 | 2011 | 3 | 0.100 |
Why?
| | Immunocompromised Host | 2 | 2020 | 7 | 0.100 |
Why?
| | Pregnancy | 4 | 2024 | 203 | 0.100 |
Why?
| | Quality of Health Care | 1 | 2010 | 13 | 0.090 |
Why?
| | Cost of Illness | 2 | 2020 | 19 | 0.090 |
Why?
| | Linear Models | 1 | 2010 | 55 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2011 | 177 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2005 | 55 | 0.090 |
Why?
| | Databases, Factual | 1 | 2010 | 105 | 0.090 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 1 | 0.090 |
Why?
| | Haemophilus Infections | 1 | 2009 | 5 | 0.090 |
Why?
| | Parents | 2 | 2021 | 149 | 0.090 |
Why?
| | Bacterial Proteins | 3 | 2017 | 8 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2010 | 41 | 0.080 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2008 | 2 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 194 | 0.080 |
Why?
| | Biomarkers | 2 | 2021 | 120 | 0.080 |
Why?
| | Virulence | 2 | 2004 | 7 | 0.080 |
Why?
| | Mycobacterium Infections | 1 | 2006 | 1 | 0.070 |
Why?
| | Mice, Inbred C3H | 2 | 2004 | 6 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2006 | 17 | 0.070 |
Why?
| | Illinois | 2 | 2015 | 4 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 21 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 8 | 0.060 |
Why?
| | Chromatography, Gas | 1 | 2004 | 1 | 0.060 |
Why?
| | Fatty Acids | 1 | 2004 | 2 | 0.060 |
Why?
| | Culture Media | 1 | 2003 | 1 | 0.060 |
Why?
| | Candida glabrata | 1 | 2003 | 1 | 0.060 |
Why?
| | Mycology | 1 | 2003 | 2 | 0.060 |
Why?
| | Candida albicans | 1 | 2003 | 3 | 0.060 |
Why?
| | Gene Amplification | 1 | 2003 | 4 | 0.060 |
Why?
| | Cricetinae | 2 | 2002 | 3 | 0.060 |
Why?
| | CHO Cells | 2 | 2002 | 3 | 0.060 |
Why?
| | DNA, Fungal | 1 | 2003 | 4 | 0.060 |
Why?
| | DNA Primers | 1 | 2003 | 27 | 0.060 |
Why?
| | Kidney | 1 | 2004 | 89 | 0.060 |
Why?
| | Mothers | 1 | 2024 | 37 | 0.060 |
Why?
| | Acceleration | 1 | 2023 | 4 | 0.060 |
Why?
| | Cytomegalovirus | 1 | 2023 | 2 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2023 | 32 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2023 | 7 | 0.060 |
Why?
| | Educational Status | 1 | 2023 | 20 | 0.060 |
Why?
| | Phenotype | 1 | 2004 | 233 | 0.060 |
Why?
| | Antibody Affinity | 1 | 2022 | 4 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 14 | 0.060 |
Why?
| | Oxygen | 1 | 2022 | 13 | 0.060 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.060 |
Why?
| | Complement System Proteins | 1 | 2002 | 5 | 0.060 |
Why?
| | Macaca nemestrina | 1 | 2002 | 1 | 0.060 |
Why?
| | Trypanosoma cruzi | 1 | 2002 | 2 | 0.060 |
Why?
| | Chagas Disease | 1 | 2002 | 2 | 0.060 |
Why?
| | Hematoma, Subdural | 1 | 2022 | 4 | 0.060 |
Why?
| | Microbiological Techniques | 2 | 2015 | 5 | 0.050 |
Why?
| | Hospitals | 1 | 2022 | 38 | 0.050 |
Why?
| | Operon | 2 | 2001 | 2 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 20 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 6 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2021 | 16 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2021 | 7 | 0.050 |
Why?
| | Antibody Specificity | 1 | 2021 | 8 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 7 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2021 | 31 | 0.050 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 8 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2021 | 11 | 0.050 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.050 |
Why?
| | Bacteria | 1 | 2021 | 9 | 0.050 |
Why?
| | Microtubules | 2 | 1999 | 5 | 0.050 |
Why?
| | Comorbidity | 1 | 2021 | 61 | 0.050 |
Why?
| | Immunization | 1 | 2021 | 23 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 33 | 0.050 |
Why?
| | Neck | 2 | 2013 | 5 | 0.050 |
Why?
| | Transcriptome | 1 | 2021 | 50 | 0.050 |
Why?
| | Dialysis Solutions | 1 | 2021 | 19 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 30 | 0.050 |
Why?
| | Catheterization | 1 | 2021 | 27 | 0.050 |
Why?
| | Self Care | 1 | 2021 | 24 | 0.050 |
Why?
| | Skin | 1 | 2020 | 13 | 0.050 |
Why?
| | Family Characteristics | 1 | 2020 | 10 | 0.050 |
Why?
| | Vacuoles | 1 | 2000 | 1 | 0.050 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2000 | 1 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2020 | 36 | 0.050 |
Why?
| | Liver | 1 | 2021 | 119 | 0.050 |
Why?
| | RNA, Ribosomal, 23S | 1 | 2019 | 1 | 0.050 |
Why?
| | Cytoskeleton | 1 | 1999 | 4 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1999 | 28 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2019 | 5 | 0.040 |
Why?
| | Premature Birth | 1 | 2019 | 5 | 0.040 |
Why?
| | Australia | 1 | 2019 | 9 | 0.040 |
Why?
| | Netherlands | 1 | 2019 | 4 | 0.040 |
Why?
| | Regression Analysis | 1 | 2018 | 56 | 0.040 |
Why?
| | Metabolic Diseases | 1 | 2018 | 11 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 340 | 0.040 |
Why?
| | Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.040 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | beta-Lactam Resistance | 1 | 2017 | 1 | 0.040 |
Why?
| | Fimbriae Proteins | 1 | 2017 | 1 | 0.040 |
Why?
| | Penicillin-Binding Proteins | 1 | 2016 | 2 | 0.040 |
Why?
| | Pharmacy Service, Hospital | 1 | 2016 | 8 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 82 | 0.040 |
Why?
| | Sequence Homology | 1 | 2015 | 2 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2015 | 3 | 0.030 |
Why?
| | Genome, Viral | 1 | 2015 | 4 | 0.030 |
Why?
| | China | 1 | 2015 | 8 | 0.030 |
Why?
| | Dyspnea | 1 | 2015 | 4 | 0.030 |
Why?
| | Colorado | 1 | 2015 | 8 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 6 | 0.030 |
Why?
| | Cough | 1 | 2015 | 7 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2015 | 16 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2015 | 14 | 0.030 |
Why?
| | Primary Health Care | 1 | 2015 | 44 | 0.030 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 2 | 0.030 |
Why?
| | Economics, Hospital | 1 | 2015 | 3 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 9 | 0.030 |
Why?
| | Cost Savings | 1 | 2015 | 10 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 94 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 88 | 0.030 |
Why?
| | Program Evaluation | 1 | 2015 | 52 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2015 | 40 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 46 | 0.030 |
Why?
| | Drainage | 1 | 2013 | 34 | 0.030 |
Why?
| | Rats | 2 | 2005 | 97 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2013 | 46 | 0.030 |
Why?
| | Diagnostic Test Approval | 1 | 2011 | 1 | 0.030 |
Why?
| | Tympanic Membrane | 1 | 2011 | 1 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2011 | 2 | 0.030 |
Why?
| | Administration, Topical | 1 | 2011 | 6 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 6 | 0.030 |
Why?
| | Otitis Media with Effusion | 1 | 2011 | 3 | 0.030 |
Why?
| | Administration, Oral | 1 | 2011 | 59 | 0.030 |
Why?
| | Recurrence | 1 | 2011 | 115 | 0.030 |
Why?
| | Cell Wall | 1 | 2010 | 1 | 0.020 |
Why?
| | Mycolic Acids | 1 | 2010 | 1 | 0.020 |
Why?
| | Pigments, Biological | 1 | 2010 | 1 | 0.020 |
Why?
| | Chaperonin 60 | 1 | 2010 | 1 | 0.020 |
Why?
| | DNA, Ribosomal Spacer | 1 | 2010 | 2 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2010 | 3 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2010 | 2 | 0.020 |
Why?
| | Africa | 1 | 2010 | 3 | 0.020 |
Why?
| | Enzymes | 1 | 2010 | 4 | 0.020 |
Why?
| | Temperature | 1 | 2010 | 10 | 0.020 |
Why?
| | Hot Temperature | 1 | 2010 | 3 | 0.020 |
Why?
| | Binding Sites | 2 | 2002 | 26 | 0.020 |
Why?
| | Bacterial Adhesion | 2 | 1999 | 2 | 0.020 |
Why?
| | Face | 1 | 2008 | 3 | 0.020 |
Why?
| | Cefoxitin | 1 | 2006 | 1 | 0.020 |
Why?
| | Doxycycline | 1 | 2006 | 1 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2006 | 1 | 0.020 |
Why?
| | Linezolid | 1 | 2006 | 2 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Acetamides | 1 | 2006 | 2 | 0.020 |
Why?
| | Oxazolidinones | 1 | 2006 | 2 | 0.020 |
Why?
| | Clarithromycin | 1 | 2006 | 3 | 0.020 |
Why?
| | Mycobacterium fortuitum | 1 | 2006 | 2 | 0.020 |
Why?
| | Amikacin | 1 | 2006 | 3 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 38 | 0.020 |
Why?
| | Uterine Diseases | 1 | 2005 | 1 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2005 | 1 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 6 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 14 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 14 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 19 | 0.010 |
Why?
| | DNA, Kinetoplast | 1 | 2002 | 1 | 0.010 |
Why?
| | Antibodies | 1 | 2002 | 15 | 0.010 |
Why?
| | Antibodies, Protozoan | 1 | 2002 | 3 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 30 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2002 | 3 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2002 | 23 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 60 | 0.010 |
Why?
| | Blood Group Antigens | 1 | 2001 | 1 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2001 | 4 | 0.010 |
Why?
| | Intestinal Diseases | 1 | 2001 | 4 | 0.010 |
Why?
| | Hemagglutinins | 1 | 2001 | 1 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2001 | 26 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 14 | 0.010 |
Why?
| | Neisseria gonorrhoeae | 1 | 1999 | 1 | 0.010 |
Why?
| | Complement C1q | 1 | 1999 | 3 | 0.010 |
Why?
| | Cattle | 1 | 1999 | 24 | 0.010 |
Why?
| | Actins | 1 | 1999 | 5 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 47 | 0.010 |
Why?
| | Cytochalasin D | 1 | 1997 | 1 | 0.010 |
Why?
| | Nocodazole | 1 | 1997 | 1 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 3 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 1997 | 36 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|